FDMT - 4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis Rare Inherited Disease | Benzinga
4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced an update on its 4D-710, an aerosolized genetic medicine for cystic fibrosis (CF) lung disease.
CF is a genetic (inherited) disease that causes sticky, thick mucus to build up in organs, including the lungs and pancreas.
Given high-level cystic fibrosis transmembrane conductance regulator (CFTR) transgene expression in all lung airway biopsies disclosed to date (significantly above normal lung CFTR levels), dose exploration continues with the evaluation of lower doses in the 4D-710 Phase 1/2 AEROW clinical trial at 5E14 vg dose (Cohort 3; n=1) and 2.5E14 vg (Cohort 4; n=1).
Phase 2 Expansion Cohort dose selection is expected in Q2 2024 based on all ...